KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Total Stockholders' Equity

Last Annual Value

78.81M

3-Year CAGR

66%

5-Year CAGR

-26%

10-Year CAGR

-14%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Stockholders' Equity

KLRS · NASDAQ
CompanyTotal Stockholders' Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
78.81M
N/A-18.9%N/A 
130.66M
14.2%-6.2%10.2%
109.97M
N/AN/AN/A
82.39M
-17.1%-21.2%N/A
60.47M
72.1%4.6%N/A
158.60M
-9.7%N/AN/A
70.71M
1.7%-25.9%-10.5%
25.98M
-48.5%-41.0%N/A
9.46M
N/AN/AN/A
42.52M
-17.8%-17.5%N/A
199.74M
6.8%11.5%22.5%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66